Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(21)
•••
Comment by Sinbobon Oct 04, 2012 2:49pm
182 Views
Post# 20448689

RE: RE: RE: RE: Buyout on one idea

RE: RE: RE: RE: Buyout on one idea

Well, 'million..', perhaps I misunderstood the Inchbury post. Maybe he meant that BTI has a great 'long'  future and I misinterpreted it. If so, mea culpa...and good for you being his supporter... I guess. It was somewhat ambiguous so I try to reply with some sort of objective (not objectionable) reference material. I was not trying to be insulting to Inchbury because some of my best friends are short...and I hope you make that million...hopefully on BTI. 

 

Oh yes, while we're on the topic of BTI, here is a positive comparison:

Serepta (SRPT) has gone from $3.50 end June to $45 recently. Not bad for a wonderful one drug promise that has impressive potential but nowhere near the potential that BTI has for launching many, many drugs as conjugates, in dozens of  therapeutic modalities. The market for BTI is multiples of the above considering global sales.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities